Stocks to watch on Tuesday: CE, IEX, SONC >>> READ MORE

Sanofi, Michael J. Fox Foundation to Test Parkinson’s Drug

The treatment will target brain disorders caused by disease


The Michael J. Fox Foundation today announced that it will team up with French drugmaker, Sanofi (NYSE:SNY) to test an experimental treatment for Parkinson’s disease.

The foundation started by the actor, who was diagnosed with young-onset Parkinson’s disease in 1991, will sponsor a clinical trial to study a drug that targets cognitive dysfunction, a severe, but lesser known symptom of the disease. Currently, not many treatments are available for cognitive impairment in Parkinson’s.

“Cognitive dysfunction is marked by a big mixed bag of pathology,” Jamie Eberling, associate director of research programs at MJFF said on the foundation’s blog. “Different processes in different parts of the brain affect individuals with Parkinson’s in different ways.”

Including the collaboration with Sanofi, the MJFF has devoted more than $16 million toward cognitive dysfunction research.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC